India is expected to be one of the first countries to develop an indigenous, injectable vaccine against swine influenza and the government has already asked the health centers to human trials, says a senior health.
"We are not concerned about what happens abroad. Our government has a plan for the vaccine by the end of this year and we will in the first countries to have such a vaccine to combat H1N1 virus, VM Katoch, Secretary of Department of Health Research, told IANS in an interview.
"India has embarked on a vaccine since April, shortly after the epidemic broke out in the world. At least three companies working on the vaccine. A company has real progress and we believe in in November, we have something in hand," he added .
Katoch said the vaccine will be available in the market for an injection at the end of the year.
In recent months, India has more than 700 cases of swine flu in Delhi and Maharashtra are the worst affected. Both countries have more than 50 percent of the total number of cases in the country.
"Who has created four strains of the drug and treatment (in India) has approved all of them. On this basis, the vaccine has been developed at three locations across the country.
Three pharmaceutical companies - Serum Institute of India (Pune), Bharat Biotech (Hyderabad) and panacea Biotech (New Delhi) - to develop the vaccine. Pune, the company has made real progress, "he said.
While the Serum Institute is developing an "egg-based vaccine, the other two are the development of cell vaccines. "But they are all available as injections," Katoch said.
When asked about human experiments, he said the Ministry of Health has already aware of the health centers in this area and all interested parties are welcome.
"After the trial period from animals older than three companies, the vaccine will be for human trials. Mag in November, we will some tests on humans."
"Before permitting, we will verify the credentials of any clinical trial, the history and effectiveness. It is a guide for the present and the clinical trial to follow the official protocol," said Secretary IANS.
He also said human trials are conducted in different centers. "There may also outside India."
Katoch, a leading Health Science, said the parties should provide a brief description of the interest, experience, expertise and infrastructure available for the implementation of phase I and phase II clinical trials or multicenter.
He said that India is ready for quick approval of the vaccine, because it is a long time to develop a drug or a vaccine. He also said that the quality should not be affected and the "security measures" should be supported.
The H1N1 has killed four so far. As at July 31, the World Health Organization has reported 162,380 cases of laboratory confirmed influenza A (H1N1) and 1154 deaths and more than 150 countries.
"We are not concerned about what happens abroad. Our government has a plan for the vaccine by the end of this year and we will in the first countries to have such a vaccine to combat H1N1 virus, VM Katoch, Secretary of Department of Health Research, told IANS in an interview.
"India has embarked on a vaccine since April, shortly after the epidemic broke out in the world. At least three companies working on the vaccine. A company has real progress and we believe in in November, we have something in hand," he added .
Katoch said the vaccine will be available in the market for an injection at the end of the year.
In recent months, India has more than 700 cases of swine flu in Delhi and Maharashtra are the worst affected. Both countries have more than 50 percent of the total number of cases in the country.
"Who has created four strains of the drug and treatment (in India) has approved all of them. On this basis, the vaccine has been developed at three locations across the country.
Three pharmaceutical companies - Serum Institute of India (Pune), Bharat Biotech (Hyderabad) and panacea Biotech (New Delhi) - to develop the vaccine. Pune, the company has made real progress, "he said.
While the Serum Institute is developing an "egg-based vaccine, the other two are the development of cell vaccines. "But they are all available as injections," Katoch said.
When asked about human experiments, he said the Ministry of Health has already aware of the health centers in this area and all interested parties are welcome.
"After the trial period from animals older than three companies, the vaccine will be for human trials. Mag in November, we will some tests on humans."
"Before permitting, we will verify the credentials of any clinical trial, the history and effectiveness. It is a guide for the present and the clinical trial to follow the official protocol," said Secretary IANS.
He also said human trials are conducted in different centers. "There may also outside India."
Katoch, a leading Health Science, said the parties should provide a brief description of the interest, experience, expertise and infrastructure available for the implementation of phase I and phase II clinical trials or multicenter.
He said that India is ready for quick approval of the vaccine, because it is a long time to develop a drug or a vaccine. He also said that the quality should not be affected and the "security measures" should be supported.
The H1N1 has killed four so far. As at July 31, the World Health Organization has reported 162,380 cases of laboratory confirmed influenza A (H1N1) and 1154 deaths and more than 150 countries.
No comments:
Post a Comment